It was recognized that PD-1 and PD-L1 are upregulated in glioma and patients with overexpressed PD-1/PD-L1 may benefit from the PD-1/PD-L1 checkpoint blockades such as nivolumab and temozolomide (Wang et al., 2019). This evidence concerns the gene PDCD1 and glioma.